慢性髓性白血病急变期RUNX1突变与独特表型、转录谱及药物反应相关
本研究通过全外显子组和RNA测序分析RUNX1突变型慢性髓性白血病急变期(BP-CML),发现PHF6和BCORL1突变、IKZF1缺失及AID/RAG介导的重排富集,干扰素和TNF信号失调,干细胞和B淋巴系因子上调,RUNX1突变原始细胞对CD19-CAR T细胞敏感,且对mTOR、BCL2、VEGFR抑制剂和糖皮质激素高度敏感,并在CRISPR/Cas9编辑的细胞系中验证。
要点
- RUNX1突变型BP-CML富集PHF6/BCORL1突变、IKZF1缺失及AID/RAG重排。
- RUNX1突变CML原代细胞干扰素和TNF信号失调,干细胞和B淋巴系因子上调。
- RUNX1突变原始细胞对CD19-CAR T细胞及mTOR、BCL2、VEGFR抑制剂和糖皮质激素敏感。
核心结论
- 本研究揭示了RUNX1突变的致病作用,并提示个性化靶向治疗和CAR T细胞免疫治疗可能是治疗RUNX1突变型BP-CML患者的有前景策略。
研究设计与样本
- 研究采用全外显子组和RNA测序分析BP-CML样本,并在CRISPR/Cas9编辑的纯合RUNX1-/-和杂合RUNX1-/mut BCR-ABL阳性细胞系中进一步验证。
主要发现
- RUNX1突变型BP-CML富集PHF6和BCORL1突变、IKZF1缺失及AID/RAG介导的重排,形成典型突变特征。
- RUNX1突变CML原代细胞中干扰素和TNF信号失调,干细胞和B淋巴系因子上调,呈现独特表型。
- RUNX1突变原始细胞在离体实验中對CD19-CAR T细胞敏感。
- 高通量药物敏感性和耐药性检测显示RUNX1突变患者白血病细胞对mTOR、BCL2和VEGFR抑制剂及糖皮质激素高度敏感。
- 上述发现在CRISPR/Cas9编辑的纯合RUNX1-/-和杂合RUNX1-/mut BCR-ABL阳性细胞系中得到进一步研究和证实。
关键数值与推荐
- RUNX1突变型BP-CML中富集PHF6和BCORL1突变、IKZF1缺失及AID/RAG介导的重排。
- RUNX1突变CML原代细胞中干扰素和TNF信号失调,干细胞和B淋巴系因子上调。
- RUNX1突变原始细胞对CD19-CAR T细胞敏感(离体实验)。
- RUNX1突变患者白血病细胞对mTOR、BCL2和VEGFR抑制剂及糖皮质激素高度敏感(高通量药物敏感性和耐药性检测)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blast-phase chronic myeloid leukemia (BP-CML) is associated with additional chromosomal aberrations, RUNX1 mutations being one of the most common. Tyrosine kinase inhibitor therapy has only limited efficacy in BP-CML, and characterization of more defined molecular subtypes is warranted in order to design better treatment modalities for this poor prognosis patient group. Using whole-exome and RNA sequencing we demonstrate that PHF6 and BCORL1 mutations, IKZF1 deletions, and AID/RAG-mediated rearrangements are enriched in RUNX1mut BP-CML leading to typical mutational signature. On transcriptional level interferon and TNF signaling were deregulated in primary RUNX1mut CML cells and stem cell and B-lymphoid factors upregulated giving a rise to distinct phenotype. This was accompanied with the sensitivity of RUNX1mut blasts to CD19-CAR T cells in ex vivo assays. High-throughput drug sensitivity and resistance testing revealed leukemia cells from RUNX1mut patients to be highly responsive for mTOR-, BCL2-, and VEGFR inhibitors and glucocorticoids. These findings were further investigated and confirmed in CRISPR/Cas9-edited homozygous RUNX1-/- and heterozygous RUNX1-/mut BCR-ABL positive cell lines. Overall, our study provides insights into the pathogenic role of RUNX1 mutations and highlights personalized targeted therapy and CAR T-cell immunotherapy as potentially promising strategies for treating RUNX1mut BP-CML patients.
引用
- Adnan Awad S, Dufva O, Ianevski A, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2020. PMID: 32782381. doi:10.1038/s41375-020-01011-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。